Rodrigo Lastra del Prado: At ESMO 2026, Javier David Benitez Fuentes Examines EU Lung Cancer Drug Approvals
Rodrigo Lastra del Prado and Javier David Benitez Fuentes

Rodrigo Lastra del Prado: At ESMO 2026, Javier David Benitez Fuentes Examines EU Lung Cancer Drug Approvals

Rodrigo Lastra del Prado, Medical Oncologist of Thoracic Tumor Unit Oncology Department at Hospital Clinico Universitario Lozano Blesa, shared on X:

“Great work of my friend Javier David Benitez Fuentes in ESMO26 applying Common Sense Oncology – CSO checklist to EU Medicines Agency approvals in Lung Cancer drugs 2020 – 2025.”

Rodrigo Lastra del Prado: At ESMO 2026, Javier David Benitez Fuentes Examines EU Lung Cancer Drug Approvals

You can also read:

ASTRIDE: Serplulimab Shows Numerically Longer Overall Survival Than Atezolizumab in US Patients With Extensive-Stage Small Cell Lung Cancer

Rodrigo Lastra del Prado: At ESMO 2026, Javier David Benitez Fuentes Examines EU Lung Cancer Drug Approvals